Sixth, the study was small and can’t be considered directive clinically. In summary, intravenous mepolizumab reduced the amount of eosinophils in blood and sputum and was connected with prednisone sparing in individuals with asthma who had sputum eosinophilia regardless of the usage of oral prednisone and high-dose inhaled corticosteroid treatment. Our little pilot study is potentially clinically directive and highlights the need for selecting patients with airway eosinophilia for the analysis of the usage of anti-eosinophil drugs in asthma.. Parameswaran Nair, M.D., Ph.D., Marcia M.M. Pizzichini, M.D., Ph.D., Melanie Kjarsgaard, R.R.T., Tag D. Inman, M.D., Ph.D., Ann Efthimiadis, M.L.T., Emilio Pizzichini, M.D., Ph.D., Frederick E. Hargreave, M.D., and Paul M. O’Byrne, M.B.: Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia Monoclonal antibodies against interleukin-5, a potent eosinophilic cytokine and growth factor, have not shown efficacy in 3 clinical trials1-3 in individuals with asthma, regardless of the effectiveness of this treatment in reducing the true number of eosinophils in the airway and blood.The exclusion criteria were pregnancy, a history of or current outward indications of an autoimmune disorder, cancer within the prior 5 years except for cutaneous squamous-cell or basal-cell cancer resolved by excision, allergic reaction to monoclonal IgG-fusion or antibodies proteins, infection with hepatitis hepatitis or B C virus or the individual immunodeficiency virus, drug abuse, fibromyalgia, clinically significant cardiac disease, diabetes mellitus requiring oral treatment or insulin, clinically significant neurologic disease, or a clinically significant psychiatric disorder.